Vectus Biosystems Appoints Dr Speranza and Raises $0.79M to Advance Fibrosis Pipeline

Leadership Upgrade to Drive Clinical and Commercial Momentum

Vectus Biosystems (ASX:VBS) has strengthened its executive ranks with the appointment of Dr Tara Speranza as CEO and CTO, effective May 2026. Dr Speranza brings over 20 years of experience spanning scientific research, drug development, biotech commercialisation, and capital markets advisory. Her prior consulting role with Vectus since August 2025 gave her a head start on the company’s lead compound VB0004 and its broader drug portfolio.

Her track record includes senior research roles at the University of Sydney and Geneva, where she focused on novel molecular targets and translating discoveries into therapies. Notably, she led a commercial partnership with Servier contributing to an anti-osteoporotic drug’s development. Transitioning into investment and advisory roles, Dr Speranza has supported healthcare companies with valuation, capital raising, and strategic transactions, positioning her to guide Vectus through upcoming clinical and commercial milestones.

Capital Injection to Accelerate VB0004 Trials and Pipeline Progress

In May 2026, Vectus completed a placement raising $791,000 through the issue of 7.91 million shares at 10 cents each. The placement attracted sophisticated investors and excluded related parties. The fresh capital is earmarked primarily to fast-track the Phase Ib clinical trial of VB0004, an antifibrotic candidate targeting fibrosis reversal in lungs, heart, and kidneys. Additional funds will support other emerging drug candidates and general working capital needs.

Strategic Sale of Renal Fibrosis Asset to XORTX Therapeutics

April 2026 saw Vectus finalise the out-licensing of its VB4-P5 renal small molecule compound to Nasdaq-listed Canadian biotech XORTX Therapeutics. As consideration, Vectus received approximately 9.9% equity in XORTX through 154,544 common shares and 692,150 prefunded warrants exercisable without further payment. Some securities are subject to lock-up periods up to 180 days.

This transaction transferred patents, IP, and data related to VB4-P5’s application in renal fibrosis and kidney disease to XORTX, while Vectus retained licenses for non-renal uses. Importantly, this deal allows Vectus to maintain exposure to future development and commercial upside of VB4-P5 and XORTX’s wider pipeline without committing additional capital.

US Regulatory Engagement to Support FDA Submissions

Post-quarter, Vectus engaged Cardinal Health Regulatory Services (CHRS) as its US regulatory agent. CHRS will serve as the primary liaison for all FDA-related activities concerning VB0004 and potentially other pipeline assets. Their remit includes preparing and facilitating FDA communications, pre-IND meetings, IND applications, and Orphan Drug Designation requests.

CHRS is a recognised US consultancy with deep expertise in FDA submissions and drug development strategy, a critical partner as Vectus pursues clinical development in the US market.

Financial Position and Cost Management

Vectus reported cash on hand of $718,000 at 30 June 2026, following operating cash outflows of $167,000 for the quarter. The company has actively reduced operating expenses, with commercialisation-related costs, patent renewals, and staff expenses totaling $74,000 during the period. Payments to related parties included the CEO’s salary and fees to a corporate services provider linked to a non-executive director.

The company holds a $450,000 loan facility from Director Maurie Stang, fully drawn and repayable without penalty upon securing alternative funding. Vectus remains focused on licensing and collaboration opportunities to sustain its development programs.